Rafael Pharmaceuticals Inc. said FDA has granted orphan drug designation to CPI-613, the company's lead Altered Energy Metabolism Directed drug candidate, for the treatment of Burkitt Lymphoma.
AstraZeneca and Merck announced positive results from the randomized, double-blind, placebo-controlled, phase III SOLO-1 trial of Lynparza (olaparib) tablets.
Genentech said that the phase III IMpower133 study met its co-primary endpoints of overall survival and progression-free survival at its first interim analysis.
Taiho Oncology Inc. and Servier announced clinical data from the pivotal phase III trial (TAGS) evaluating LONSURF (trifluridine and tipiracil, TAS-102) plus best supportive care (BSC) versus placebo plus BSC in patients with previously treated metastatic gastric cancer refractory to standard therapies.
To ensure the well-being and safety of healthcare providers and patients, the Oncology Nursing Society developed the Toolkit for Safe Handling of Hazardous Drugs for Nurses in Oncology.
Case Comprehensive Cancer Center has earned NCI's highest rating and $31.9 million in grants.
Tahoe Hospital Management Co. Ltd. and UPMC reached a five-year agreement under which UPMC will assist in the planning and operation of an expanded cancer center within an existing private hospital in Beijing.
UPMC and the University of Pittsburgh launched an advanced genome sequencing center to support clinical diagnostics and research initiatives in precision medicine and immunotherapy.
After more than two decades of providing cancer care in New Jersey, Memorial Sloan Kettering Cancer Center announced that its newest outpatient treatment center, in Bergen County, will open in the coming weeks.
